Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1995-06-01
1998-11-24
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
4241401, 4241751, 546130, A61K 39385, A61K 3900, A61K 39395, C07P45102
Patent
active
058403078
ABSTRACT:
Hapten-carrier conjugates capable of eliciting anti hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Anti-hapten antibodies elicited compete with free hapten upon subsequent challenge of a vaccinated individual. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
REFERENCES:
patent: 4197237 (1980-04-01), Leute
patent: 4235864 (1980-11-01), Kaul et al.
patent: 4375414 (1983-03-01), Stranievitz
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4666837 (1987-05-01), Harford
patent: 4791067 (1988-12-01), Sheiman
patent: 4813924 (1989-03-01), Strahilevitz
patent: 4834973 (1989-05-01), Strahilevitz
patent: 5019384 (1991-05-01), Gefter
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5256409 (1993-10-01), Blincko
patent: 5268276 (1993-12-01), Holmgren
patent: 5283066 (1994-02-01), Liu et al.
Ambre, et al., "A Kinetic Model of Benzoylechonine Disposition after Cocaine Administration in Humans", Journal of Analytical Toxicology, vol. 15, 1991, 17-20.
Berkower, "Synthetic T Cell Epitope Peptides Used for Desensitization: Theoretical and Clinical Considerations", Paul-Ehrlich-Institut, Sep. 7-10, 1993.
Bonese, "Changes in heroin self-administration of a rhesus monkey after morphine immunization", Nature, vol. 252, Dec. 1974.
Gallacher, "A potential vaccine for cocaine abuse prophylaxis?", Immunopharm., vol. 27, 1994, 79-81.
Holmgren, et al., "Stretehies for the induction of Immune Responses at Mucosal Surfaces . . . ", Am. J. Trop. Med. Hyg., 1994, pp. 42-54.
Inaba, "Cocaine: Pharmacokinetics and biotransformation in man", SFBS Symposium on Frontiers in Cocaine Research, Quebec, Canada, Jun. 15, 1988, pp. 1154-1157.
Jatlow, "Cocaine: Analysis, Pharmacokinetics, and Metobolic Disposition", The Yale Journal of Biology and Medicine, vol. 61, 1988, pp. 105-113.
Jindal, et al., "Mass Spectrometric Studies of Cocaine Disposition in Animals . . . ", Journal of Pharmaceutical Sciences, vol. 78, No. 12, 1989, pp. 1009-1014.
Kantak, et al., "Acute and multiple injection effects of magnesium on resonding maintained by Cocaine, . . . ", Pharm. Biochem. and Behavior, vol. 41, 1992, pp. 415-423.
Manganaro, et al., "Oral Immunization: Turning Fantasy into Reality", Int. Arch. Immunol., vol. 103, 1994, pp. 223-233.
Stok, et al., "Conversion of orally induced supression of the mucosal immune response to ovalbumin into stimulation by conjugating . . . ", Vaccine, vol. 12, 1994, No. 6, pp. 521-526.
Slos, et al., "Recombinant cholera toxin B subunit in Escherichia coli: high-level secretion, purification and characterization", Protein Expresion and Purification, vol. 5, 1994, pp. 518-526.
Witkin, "Pharmacotherapy of Cocaine Abuse: Preclinical Development", Neurosci. and Biobehav. Reviews, vol. 18, No. 1, 1994, pp. 121-142.
Jones-Witters and Witters, Drugs and Society -- A Biological Perspective, Wadsworth Health Sciences Division, 1983, Wadsworth, Inc., Belmont, California 94002, pp. 142-147.
Wu, et al., "Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen . . . ", Vaccine, 1994, vol. 12, No. 3, pp. 215-222.
Currueru, R. et al., (1993) Society for Neuroscience 754.4 (Abstract).
Bagasra et al. Immunopharmacology (1992) vol. 23 pp. 173-179.
Exley Mark Adrian
Fox Barbara Saxton
Gefter Malcolm L.
Greenstein Julia Lea
Powers Stephen P.
Channing Stacey L.
Craig Anne I.
Housel James C.
ImmuLogic Pharmacuetical Corp.
Klein Christopher A.
LandOfFree
Hapten-carrier conjugates for use in drug-abuse therapy and meth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hapten-carrier conjugates for use in drug-abuse therapy and meth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hapten-carrier conjugates for use in drug-abuse therapy and meth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1699177